Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
PharmAla completes delivery of a Phase 3 clinical trial contract after finishing release testing on an australian-made batch of LaNeo MDMA.
-
PharmAla launches new web portal for MDMA prescribers and appoints a new COO
-
PharmAla releases Q2 financial statements showing increased customer deposits, shipments
-
PharmAla sidesteps tariff risk and expands clinical operations in the United States by contracting with Sharp Clinical Services as distribution partner
-
PharmAla completes shipment of MDMA to University of Washington, to be used in a Narcissism clinical trial. It also appoints Ali Taghva as CCO.
-
PharmAla completes historic first shipment of MDMA from Canada to USA for use in a UCLA Clinical Trial
-
PharmAla to supply the STRONG STAR Consortium with new 20mg MDMA dose to treat active-duty military personnel in a clinical trial
-
PharmAla partners with Merhavim and MAPS Israel for innovative MDMA PTSD clinical trial data sharing partnership in wake of Gaza Ceasefire
-
PharmAla announces private placement financing
-
PharmAla contracted to sell MDMA to Mt. Sinai Hospital, NY. Terminates Contract with CCrest Labs.